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Introduction: A prespecified analysis of the large, randomized,
phase III study in advanced non-small cell lung cancer showed
significant improvement in survival for nonsquamous patients treated
with pemetrexed/cisplatin versus gemcitabine/cisplatin. Selected grade
3/4 toxicities and resource utilization favored pemetrexed in the overall
population, but detailed safety results by histology have not been
reported.
Methods: Treated patients were included in this analysis of safety
by histology. At each cycle, adverse events were assessed, and
concomitant medications, transfusions, and hospitalizations were
recorded. Measures were summarized by histology and compared
between arms with Fisher’s exact test.
Results: When analyzed by squamous and nonsquamous histology,
safety and resource utilization for each treatment arm paralleled
those of the overall population. Selected toxicities did not vary by
histology. Concomitant medication use and hospitalizations were
also very similar to the patterns observed in the overall population.
Conclusions: Although previous efficacy analyses showed a signif-
icant pemetrexed treatment advantage for nonsquamous patients,
results of this analysis indicate that safety and resource utilization do
not vary by histology and are consistent with the overall population.
The safety and resource utilization of patients treated with pem-
etrexed/cisplatin are predictable, reproducible, and consistent with
the established favorable safety profile of pemetrexed, regardless of
histology.
Key Words: Cisplatin, Histology, Non-small cell lung cancer,
Pemetrexed, Resource utilization, Safety.
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The majority of patients with non-small cell lung cancer(NSCLC) present with locally advanced (stage IIIB) or
metastatic (stage IV) disease, for which platinum-based doublet
chemotherapy is recommended as a first-line treatment.1–3 Plat-
inum doublets comprise cisplatin or carboplatin combined with
a third-generation cytotoxic agent such as pemetrexed, gemcit-
abine, vinorelbine, irinotecan, or taxane.4–13 Select patients with
nonsquamous NSCLC may also be candidates for a platinum
doublet in combination with bevacizumab.2,3 In patients with
NSCLC, platinum-based doublets have demonstrated compara-
ble efficacy with a range of toxicity profiles when evaluated
head-to-head in phase III studies.8,10–14 Given the diversity of
toxicities, resource utilization data can be beneficial to charac-
terize the impact of various toxicities that may affect the choice
of first-line treatment.
The efficacy and tolerability of pemetrexed have been
well established in thoracic tumors for several indications. Pem-
etrexed is approved for use in combination with cisplatin for
unresectable mesothelioma,15 as a single agent for second-line
and maintenance treatment of nonsquamous NSCLC,16,17 and in
combination with cisplatin for first-line treatment of advanced
nonsquamous NSCLC.14 The latter indication is based on the
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results of a large phase III study of pemetrexed/cisplatin versus
gemcitabine/cisplatin in chemonaïve patients for first-line treat-
ment of stage IIIB/IV NSCLC,14 which demonstrated noninfe-
rior efficacy in the intent-to-treat population and better tolera-
bility for pemetrexed/cisplatin. In addition, resource utilization
favored the pemetrexed combination.
In a prespecified analysis of the same study,14 a signif-
icant treatment-by-histology interaction was observed, which
showed a significant survival advantage for patients with
nonsquamous histology treated with pemetrexed/cisplatin.18
Squamous patients in the study, however, had shorter survival
on pemetrexed/cisplatin compared with gemcitabine/cispla-
tin. Analyses of other phase III studies in multiple treatment
indications for NSCLC have also shown a treatment-by-
histology interaction for pemetrexed.18,19
In the primary report of this study, Scagliotti et al.14
indicated that safety within the histologic groups was gener-
ally consistent with the overall safety results. This article
further explores the safety profile and resource utilization of
pemetrexed-based therapy by histology, analyzing the data
from the phase III, randomized, noninferiority study compar-
ing pemetrexed/cisplatin and gemcitabine/cisplatin in che-
monaïve patients with advanced NSCLC.
PATIENTS AND METHODS
Patients
The data for this comprehensive analysis of safety and
resource utilization are from the randomized, open-label,
global, phase III study comparing pemetrexed/cisplatin with
gemcitabine/cisplatin, which was previously published.14 The
study included chemonaïve patients with stage IIIB or IV
NSCLC, an Eastern Cooperative Oncology Group perfor-
mance status of 0 or 1, and adequate bone marrow reserve
and organ function. Exclusion criteria included National
Cancer Institute Common Toxicity Criteria20 (version 2.0)
grade 1 peripheral neuropathy, progressive brain metasta-
ses, or uncontrolled third-space fluid retention. The protocol
was conducted according to the Declaration of Helsinki and
Good Clinical Practice guidelines and was approved by each
participating institution’s ethics review board. All patients
signed written informed consent before treatment.
Treatment and Study Design
Patients received either pemetrexed (500 mg/m2 intrave-
nously [IV]) followed by cisplatin (75 mg/m2 IV) on day 1 or
gemcitabine 1250 mg/m2 on days 1 and 8 with cisplatin (75
mg/m2 IV) on day 1. Both regimens were administered every 3
weeks, for a maximum of six cycles. All patients received
dexamethasone prophylaxis and oral folic acid (350–1000 g)
daily and a vitamin B12 injection (1000 g) every 9 weeks,
beginning 1 to 2 weeks before the first dose and continuing until
3 weeks after the last dose of study treatment.
Supportive care was provided at the investigator’s dis-
cretion. Use of 5-HT3 antagonists was encouraged. Routine
use of colony-stimulating factors was not permitted, but it
could be administered according to American Society of
Clinical Oncology guidelines.21 Use of erythropoiesis-stimu-
lating agents (ESAs) was permitted, with no specific guide-
lines or recommendations. Efficacy analyses, including by
histologic groups, have been previously reported.14,18,19,22
Safety and Resource Utilization Assessments
and Analyses
For safety and resource utilization, patients were as-
sessed at each cycle and at 30 days after poststudy discon-
tinuation. Adverse events (AEs) were assessed using National
Cancer Institute Common Toxicity Criteria version 2.0. Cau-
sality was determined by the investigator. The evaluation of
resource utilization included concomitant medications, trans-
fusions, and AE-related hospitalizations. Investigator-
reported NSCLC histology was grouped for statistical anal-
ysis into four main categories: adenocarcinoma, large cell
carcinoma, squamous cell carcinoma, and other NSCLC/not
otherwise specified, consistent with published guidelines.23,24
For these analyses, resource utilization and drug-related AEs
were grouped and evaluated by squamous and nonsquamous
(adenocarcinoma, large cell carcinoma, and other/not other-
wise specified) NSCLC histology and compared between
arms with Fisher’s exact test. Safety analyses were performed
for patients who received at least one dose of study treatment.
RESULTS
Patient Characteristics
A total of 1725 patients (pemetrexed/cisplatin  862,
gemcitabine/cisplatin 863) were enrolled from July 2004 to
December 2005. The majority of patients, 1051 (61%), were
from Europe. Safety analyses were done for 97.3% (839
patients) and 96.2% (830 patients) of the patients treated with
pemetrexed/cisplatin and gemcitabine/cisplatin, respectively.
The baseline patient and disease-related characteristics were
well balanced between the two treatment arms and between
the squamous and nonsquamous histologic groups (Table 1).
Treatment
The number of cycles of pemetrexed/cisplatin and gem-
citabine/cisplatin delivered were similar between arms and
between the two histologic groups. On both treatment arms,
the median number of cycles was five for all patients and for
nonsquamous patients; however, the median was different for
squamous patients: four for patients on the pemetrexed/
cisplatin arm and five for patients on the gemcitabine/cispla-
tin arm.
The relative mean dose intensity was similar when
comparing all patients, squamous patients, and nonsquamous
patients, with approximately 1% difference in the mean dose
intensity between histologic groups for a given drug (Ta-
ble 2). The mean dose intensity for gemcitabine was consis-
tently lower than that for pemetrexed (e.g., 85.8% versus
94.8% for all patients), as was the mean dose intensity for
cisplatin on the gemcitabine arm compared with the mean
dose intensity for cisplatin on the pemetrexed arm (e.g.,
93.5% versus 95.0% for all patients).
Safety
The incidence of selected grade 3/4 toxicities did not
vary by histologic group and paralleled results in the overall
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population (Table 3). The incidence of neutropenia, throm-
bocytopenia, and febrile neutropenia was significantly lower
for patients treated with pemetrexed/cisplatin in both histo-
logic groups and in the overall population. The incidence of
anemia was significantly lower for nonsquamous patients
treated with pemetrexed/cisplatin compared with nonsqua-
mous patients treated with gemcitabine/cisplatin, which par-
alleled the overall population. Squamous patients treated with
pemetrexed/cisplatin had a slightly lower rate of anemia
compared with those treated with gemcitabine/cisplatin; how-
ever, it was not statistically significant. The incidence of
infections with and without grade 3/4 neutropenia was low
TABLE 1. Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin: Baseline Patient and











Median age (yr) 60.7 62.8 59.9 63.3
Female/male (%) 36/64 15/85 33/67 21/81
Ever/never smoker/unknown (%) 70/18/12 82/7/12 71/17/13 82/7/11
Stage IIIB/IV (%) 21/79 32/68 23/77 28/72
ECOG PS 0/1 (%) 35/65 36/64 37/62 31/69
White/Eastern Asian/other (%) 76/14/10 81/12/7 79/12/10 80/11/9
a Because of rounding, percentages may not total 100.
ECOG PS, Eastern Cooperative Oncology Group performance status.
TABLE 2. Pemetrexed Plus Cisplatin versus Gemcitabine
Plus Cisplatin: Dose Intensity
Treatment
Mean Dose Intensity (%)
Overall Nonsquamous Squamous
Pemetrexed 94.8 95.1 94.1
Cisplatin 95.0 95.1 94.8
Gemcitabine 85.8 86.1 85.0
Cisplatin 93.5 93.2 94.4
















Anemia (%) 5.6 9.9 5.0 10.2 7.2 9.0
p 0.001 0.001 0.497
Neutropenia (%) 15.1 26.7 14.9 25.6 15.7 29.9
p 0.001 0.001 0.001
Thrombocytopenia (%) 4.1 12.7 3.6 10.8 5.1 17.6
p 0.001 0.001 0.001
Febrile neutropenia (%) 1.3 3.7 1.3 3.3 1.3 5.0
p 0.002 0.034 0.028
Infection with grade 3/4 neutropenia (%) 0.7 0.7 0.5 0.3 1.3 1.8
p 1.000 0.686 0.717
Infection without grade 3/4 neutropenia (%) 0.6 0.7 0.3 0.5 1.3 1.4
p 0.773 1.000 1.000
Fatigue (%) 6.7 4.9 6.6 4.4 6.8 6.3
p 0.143 0.103 0.853
Nausea (%) 7.2 3.9 7.9 4.3 5.1 2.7
p 0.004 0.008 0.233
Vomiting (%) 6.1 6.1 6.3 6.1 5.5 6.3
p 1.000 0.906 0.843
Anorexia (%) 2.4 0.7 1.8 0.5 3.8 1.4
p 0.009 0.034 0.143
a Selection of toxicities based on association with resource utilization presented.
PC, pemetrexed/cisplatin; GC, gemcitabine/cisplatin.
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for all patients, regardless of treatment, and was similar
between treatment and histologic groups.
In the overall population, anorexia and nausea were
significantly higher for pemetrexed/cisplatin than gemcitab-
ine/cisplatin; higher rates were also observed for pemetrexed/
cisplatin in both histologic groups (significantly higher for
nonsquamous patients treated with pemetrexed/cisplatin com-
pared with gemcitabine/cisplatin). The incidence of vomiting
was similar between treatment arms and histologic groups.
Fatigue was numerically worse for pemetrexed/cisplatin;
however, the difference was not statistically significant.
Investigators categorized each death that occurred dur-
ing study treatment as because of study disease, possibly
because of study drug, or because of other causes. Overall,
relatively few deaths (7%) occurred during study treatment.
Deaths that occurred during treatment that were attributed to
study-drug toxicity were similar between arms, occurring in
nine patients (1.0%) on pemetrexed/cisplatin and six patients
(0.7%) on gemcitabine/cisplatin. On the pemetrexed/cisplatin
arm, six of the nine deaths were in patients with nonsqua-
mous histology, whereas all the deaths on the gemcitabine/
cisplatin arm were in patients with nonsquamous histology.
Concomitant Therapy and Hospitalizations
The use of concomitant medications is presented in
Figure 1. The use of granulocyte colony-stimulating factor/
granulocyte macrophage colony-stimulating factors (G-CSF/
GM-CSF) and ESAs was significantly lower (p  0.012) for
the pemetrexed/cisplatin arm in both histologic groups, with
the exception of the G-CSF/GM-CSF squamous group (p 
0.141). The use of antiemetics and antibiotics in the squa-
mous and nonsquamous groups was similar to that in the
overall population, with the only significant difference (p 
0.040) being higher use of antiemetics for squamous patients
on the pemetrexed/cisplatin arm relative to the gemcitabine/
cisplatin arm (Figure 1).
The use of transfusions was significantly lower on the
pemetrexed/cisplatin arm in the overall population and in
both histologic groups (p  0.016; Figure 2). Most of the
transfusions received were red blood cell transfusions.
Hospitalizations because of AEs, both regardless of
causality and drug-related hospitalizations, in the squamous
and nonsquamous groups followed the same hospitalization
pattern as in the overall population and were not significantly
different between treatment arms (Figure 3). Hospitalizations,
regardless of causality, ranged from 31.1 to 37.1% for all
groups, with slightly fewer hospitalizations for the pem-
etrexed/cisplatin arm. Drug-related hospitalizations repre-
sented less than half of the total hospitalizations and were
slightly lower for the pemetrexed/cisplatin arm in the overall
FIGURE 1. Pemetrexed plus cisplatin versus gemcitabine plus cisplatin: use of antiemetics (A), erythropoiesis-stimulating
agents (B), G-CSF/GM-CSF (C), and antibiotics (D). G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte mac-
rophage colony-stimulating factor; PC, pemetrexed/cisplatin; GC, gemcitabine/cisplatin.
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and squamous groups, but they were numerically higher (14.4
versus 13.0%) for the pemetrexed/cisplatin arm in the
nonsquamous group.
DISCUSSION
In a prespecified analysis of the large, randomized,
noninferiority study comparing pemetrexed/cisplatin with
gemcitabine/cisplatin in the first-line treatment of advanced
NSCLC, nonsquamous patients treated with pemetrexed/cis-
platin showed a significant improvement in survival com-
pared with gemcitabine/cisplatin. Squamous patients had
shorter survival on pemetrexed/cisplatin compared with gem-
citabine/cisplatin.14,18 An analysis of treatment-by-histology
interaction in the study indicated a differential treatment effect
for pemetrexed/cisplatin according to histology.18 Analyses of
both second-line and maintenance therapy studies have also
demonstrated a favorable pemetrexed treatment effect in patients
with advanced nonsquamous NSCLC.17–19,22 Although a defin-
itive explanation for this pemetrexed treatment effect remains
unknown, many discussions suggest that it is based on the
biology of NSCLC tumors.18,25–30
The differential effect for pemetrexed that was shown
previously for efficacy parameters, however, was not observed
for safety and resource utilization measures when analyzed
according to NSCLC histology. In both this study and the large,
phase III pemetrexed maintenance study in NSCLC, resource
utilization and AEs in the histologic groups were generally
consistent with those in the overall population.14,17,31
In the overall population of the pemetrexed/cisplatin
versus gemcitabine/cisplatin study, the pemetrexed/cisplatin
arm demonstrated a more favorable safety profile and less
resource utilization compared with the gemcitabine/cisplatin
arm.14 There were significantly lower incidences of drug-
related grade 3/4 hematologic toxicities and febrile neutrope-
nia, even though the patients on both arms received a similar
number of treatment cycles. In addition, patients treated with
pemetrexed/cisplatin required significantly fewer transfusions
and hematologic supportive care interventions (i.e., ESAs and
G-CSF/GM-CSF) than did those on the gemcitabine/cisplatin
arm. The lack of difference in the use of antiemetics suggests
that prophylaxis was used consistently between arms, which
reflects standard practice for cisplatin administration. Antibi-
otic use and non–drug-related hospitalizations also did not
differ between arms, perhaps because of associated comor-
bidities and disease-related complications (such as pneumo-
nia) in this population. Although a higher rate of hospitaliza-
tion in the gemcitabine/cisplatin arm might be expected, the
higher rates of transfusions and growth factor use on the
gemcitabine/cisplatin arm may have decreased the need for
hospitalizations because of hematologic toxicity.
In this analysis of safety and resource utilization ac-
cording to histology, the same favorable toxicity profile for
pemetrexed/cisplatin emerged as that seen in the overall
population, accompanied by a similar reduction in resource
utilization in both histologic groups. When analyzed accord-
ing to squamous and nonsquamous histology, safety and
resource utilization measures paralleled those of the overall
population. In the histologic groups, the baseline patient and
disease characteristics, number of treatment cycles delivered,
dose intensity, incidence of grade 3/4 toxicities, concomitant
therapy administration, and hospitalizations were very similar to
the patterns observed in the overall population. Although nu-
merically consistent, the lack of statistical significance in the
squamous group may be attributed to its smaller sample size.
Given that this was an international trial conducted in
26 countries, patterns of resource utilization would be ex-
pected to vary by country. Additional analyses of resource
FIGURE 2. Pemetrexed plus cisplatin versus gemcitabine
plus cisplatin: transfusions. PC, pemetrexed/cisplatin; GC,
gemcitabine/cisplatin.
FIGURE 3. Pemetrexed plus cisplatin versus gemcitabine plus cisplatin: hospitalizations because of adverse events, regardless
of causality (A) and drug-related (B). PC, pemetrexed/cisplatin; GC, gemcitabine/cisplatin.
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utilization and safety in this study by geographic region,
however, demonstrated a consistent pattern that favored pem-
etrexed/cisplatin.32,33
One major limitation to these analyses should be noted.
This phase III trial was designed with overall survival as its
primary endpoint and was powered accordingly to demon-
strate noninferiority. As such, the study was not designed or
powered to detect differences in safety or resource utilization
in the overall population or in the histologic groups. Thus, p
values are presented here to aid the reader in determining the
strength of the findings presented and should be considered
with all available information regarding pemetrexed/cisplatin
and gemcitabine/cisplatin.
The results of these analyses suggest that the observed
safety and resource utilization reflect a host-based phenom-
enon; that is, they are the result of individual patient tolerance
of therapy rather than an expression of tumor biology. It may
be beneficial to explore these observations further by analyz-
ing more phase III randomized studies in advanced NSCLC
according to histology. However, the consistency of the
results presented here, in addition to those for the large phase
III maintenance study of pemetrexed,18,19,22 is compelling.
There is a significant survival advantage for patients
with nonsquamous histology treated with pemetrexed, for which
tumor biology-based hypotheses have been suggested.18,25–30
However, our analyses indicate that the safety and resource
utilization for patients with advanced NSCLC do not vary
according to histology. These results demonstrate that the safety
profile of pemetrexed/cisplatin therapy is similar regardless of
histologic group. In general, the safety and resource utilization
of patients treated with pemetrexed/cisplatin are predictable,
reproducible, and consistent with the established safety profile of
pemetrexed. These results reflect the favorable safety profile of
pemetrexed/cisplatin, with low use of transfusions and concom-
itant medications, regardless of histologic group.
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